I presented results from a pilot study of TIL therapy, so Lifileucel , an autologous TIL therapy product in sarcoma. And so we looked at, in the end, 12 patients is what we presented at the data cutoff who were harvested for TIL expansion and underwent the enrollment and the whole process. And so what we found was 10 patients were able to be infused. And so the primary question was feasibility and safety...
I presented results from a pilot study of TIL therapy, so Lifileucel , an autologous TIL therapy product in sarcoma. And so we looked at, in the end, 12 patients is what we presented at the data cutoff who were harvested for TIL expansion and underwent the enrollment and the whole process. And so what we found was 10 patients were able to be infused. And so the primary question was feasibility and safety. And so that was really important. We met the feasibility endpoint. And of the 10 patients who were infused, eight were infused with specification product. And in total, there were four partial responses. So depending on your denominator, there were either four out of eight or four out of 10 responses in the response rate. The primary endpoint, though, was really, as I mentioned, feasibility and safety. And in terms of safety, all patients did have expected grade four cytopenias. These are self-limiting and likely due to the lymphodepletion chemotherapy. We also had IL-2 toxicity as that’s used in immunotherapy to support the product once it’s infused. But again, that was self-limiting and all patients recovered. There were no treatment-related deaths. And so that was the primary endpoints of the study. I mentioned the efficacy endpoints. Those are actually secondary endpoints. So the study was not engineered to really interrogate the efficacy of the product. We did see that signal for partial responders. I think what’s most important about that is the responses were durable, meaning all of the responses at the time of the data cutoff for this presentation were ongoing. The longest duration of response was 46 weeks, and the longest time a patient was on study without any other treatment was 15 months. And so, and again, that’s the limit there is really just the data cutoff. And so I think that’s really encouraging because in our world, again, these patients are treated later line. And so later line, metastatic patients, first line even, the progression-free survival is five to six months response rates second line and beyond or ten percent or less and so that’s why it was so encouraging to see those efficacy early efficacy signals
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.